| Total | Methylation level | P value | Methylated | P value |
---|---|---|---|---|---|
Patients (N) | 100 | Â | Â | 27 | Â |
IPSS karyotype | 37 | Â | 0.360 | 9 | 0.298 |
 Good | 22 | 0.14 (0 to 2.72) |  | 4 |  |
 Intermediate | 9 | 0.24 (0 to 0.80) |  | 4 |  |
 Poor | 6 | 0.04 (0 to 0.24) |  | 1 |  |
BM blast (%) | Â | Â | 0.098 | Â | <0.001 |
 <5 | 75 | 0.47 (0 to 1.51) |  | 10 |  |
 5 to 10 | 13 | 0.84 (0 to 3.79) |  | 8 |  |
 11 to 19 | 12 | 1.03 (0 to 2.80) |  | 9 |  |
IPSS cytopenias | Â | Â | 0.734 | Â | 0.787 |
 0/1 | 22 | 0.24 (0 to 2.80) |  | 5 |  |
 2/3 | 78 | 0.20 (0 to 3.79) |  | 22 |  |
IPSS risk group | 35 | Â | 0.007 | 9 | 0.002 |
 Low-risk (low/int-1) | 24 | 0.03 (0 to 0.76) |  | 2 |  |
 High-risk (Int-2/high) | 11 | 0.43 (0 to 2.72) |  | 7 |  |
WHO subtype | 100 | Â | Â | 27 | Â |
Risk | Â | Â | 0.000 | Â | <0.001 |
 Low risk | 70 | 0.06 (0 to 1.51) |  | 9 |  |
 High risk | 30 | 0.54 (0 to 3.79) |  | 18 |  |
Subtype | Â | Â | 0.000 | Â | <0.001 |
 RA | 41 | 0.04 (0 to 0.59) |  | 4 |  |
 RCMD | 22 | 0.06 (0 to 0.76) |  | 4 |  |
 RARS | 7 | 0.22 (0 to 1.51) |  | 1 |  |
 RAEB-1 | 21 | 0.41 (0 to 3.79) |  | 11 |  |
 RAEB-2 | 9 | 0.8 (0 to 2.8) |  | 7 |  |